Einzeltreffer — DigiBib

Purpose: Cell-free circulating tumor DNA (ctDNA) in plasma enables rapid and repeat testing of actionable mutations. Next-generation sequencing (NGS) is an attractive platform for multiplex sequencing capabilities compared to traditional methods such as PCR. The purpose of this study is to evaluate the value of the NGS-based ctDNA assay and to identify the genomic alteration profile of ctDNA in real-world Chinese non-small cell lung (NSCLC) patients.

Methods: In total, 294 Chinese patients with pathological diagnosis of Phase III-IV NSCLC were enrolled. 3-4 mL peripheral blood was collected and NGS-based analysis was carried out using a 20-gene panel. The analytical sensitivity and specificity of ctDNA NGS-based assay was validated using droplet digital PCR (ddPCR).

Results: We have tested 570 sites from 286 samples using ddPCR, which included 108 positive sites and 462 negative sites from NGS results, and the concordance rate was 99.8% (418/419) for single-nucleotide variants (SNVs) and 96.7% (146/151) for insertions and deletions (InDels). The most frequent genes were TP53 (32%), EGFR (31.97%), KRAS (6.46%), PIK3CA (4.76%), and MET (4.08%). Exon 19 deletion (19del) was the most common alteration in EGFR and G12C was the most common alteration in KRAS. Furthermore, the detection rate of TP53 was higher in the male and patients with squamous cell carcinoma. We also found the prevalence of TP53 in L858R was higher than in 19del (61.29% vs. 40%; p = 0.1115).

Conclusion: The results indicate that the results of NGS-based ctDNA assay are highly consistent with ddPCR. In Chinese NSCLC patients, TP53 mutation was more frequently associated with male and squamous cell carcinoma. The prevalence of concomitant mutations in L858R may be different from that in 19del.

Titel:	Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
Autor/in / Beteiligte Person:	Xi, Y ; Bai, Z ; Gao, S ; Guo, J ; Zhang, Z ; Zhang, H ; Qu, L ; Xu, B ; Wang, W ; Shan, G ; Cui, W ; Bai, W ; Ji, X
Link:	View record at Springer (Volltext)
Zeitschrift:	Journal of cancer research and clinical oncology, Jg. 149 (2023-09-01), Heft 11, S. 8573-8580
Veröffentlichung:	Berlin ; New York : Springer-Verlag., 2023
Medientyp:	academicJournal
ISSN:	1432-1335 (electronic)
DOI:	10.1007/s00432-023-04794-z
Schlagwort:	Humans Male Biomarkers, Tumor genetics East Asian People ErbB Receptors genetics Genomics High-Throughput Nucleotide Sequencing methods Mutation Proto-Oncogene Proteins p21(ras) genetics Female Carcinoma, Non-Small-Cell Lung genetics Carcinoma, Non-Small-Cell Lung diagnosis Carcinoma, Squamous Cell genetics Circulating Tumor DNA genetics Lung Neoplasms pathology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [J Cancer Res Clin Oncol] 2023 Sep; Vol. 149 (11), pp. 8573-8580. <i>Date of Electronic Publication: </i>2023 Apr 25. MeSH Terms: Carcinoma, Non-Small-Cell Lung* / genetics ; Carcinoma, Non-Small-Cell Lung* / diagnosis ; Carcinoma, Squamous Cell* / genetics ; Circulating Tumor DNA* / genetics ; Lung Neoplasms* / pathology ; Humans ; Male ; Biomarkers, Tumor / genetics ; East Asian People ; ErbB Receptors / genetics ; Genomics ; High-Throughput Nucleotide Sequencing / methods ; Mutation ; Proto-Oncogene Proteins p21(ras) / genetics ; Female References: Aggarwal C, Rolfo CD, Oxnard GR, Gray JE, Sholl LM, Gandara DR (2021) Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nat Rev Clin Oncol 18(1):56–62. https://doi.org/10.1038/s41571-020-0423-x. ; Chen H, Wang A, Wang J, He Z, Mao Y, Liu L (2020) Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data. J Cancer Res Clin Oncol 146(7):1867–1876. https://doi.org/10.1007/s00432-020-03192-z. (PMID: 10.1007/s00432-020-03192-z32221744) ; Cho BC, Loong HHF, Tsai CM, Teo MLP, Kim HR, Lim SM, Park K (2022) Genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumor DNA (ctDNA) in clinical practice. Curr Oncol 29(3):2154–2164. https://doi.org/10.3390/curroncol29030174. (PMID: 10.3390/curroncol29030174353233748946965) ; Ding PN, Becker T, Bray V, Chua W, Ma Y, Xu B, Roberts T (2019) Plasma next generation sequencing and droplet digital PCR-based detection of epidermal growth factor receptor (EGFR) mutations in patients with advanced lung cancer treated with subsequent-line osimertinib. Thorac Cancer 10(10):1879–1884. https://doi.org/10.1111/1759-7714.13154. (PMID: 10.1111/1759-7714.13154314147296775001) ; Esposito Abate R, Frezzetti D, Maiello MR, Gallo M, Camerlingo R, De Luca A, Normanno N (2020) Next generation sequencing-based profiling of cell free DNA in patients with advanced non-small cell lung cancer: advantages and pitfalls. Cancers (basel). https://doi.org/10.3390/cancers12123804. (PMID: 10.3390/cancers1212380433348595) ; Feng WN, Gu WQ, Zhao N, Pan YM, Luo W, Zhang H, Deng YM (2018) Comparison of the SUPERARMS and droplet digital PCR for detecting EGFR mutation in ctDNA from NSCLC patients. Transl Oncol 11(2):542–545. https://doi.org/10.1016/j.tranon.2018.02.007. (PMID: 10.1016/j.tranon.2018.02.007295256315884193) ; Gobbini E, Swalduz A, Levra MG, Ortiz-Cuaran S, Toffart AC, Perol M, Saintigny P (2020) Implementing ctDNA analysis in the clinic: challenges and opportunities in non-small cell lung cancer. Cancers (basel). https://doi.org/10.3390/cancers12113112. (PMID: 10.3390/cancers1211311233139612) ; Hong S, Gao F, Fu S, Wang Y, Fang W, Huang Y, Zhang L (2018) Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer. JAMA Oncol 4(5):739–742. https://doi.org/10.1001/jamaoncol.2018.0049. (PMID: 10.1001/jamaoncol.2018.0049295965445885210) ; Hou H, Qin K, Liang Y, Zhang C, Liu D, Jiang H, Liu K, Zhu J, Lv H, Li T, Zhang X (2019) Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC. Cancer Manag Res 11:5665–5675. https://doi.org/10.2147/CMAR.S201513. (PMID: 10.2147/CMAR.S201513314173106594053) ; Jiang J, Adams HP, Yao L, Yaung S, Lal P, Balasubramanyam A, Palma JF (2020) Concordance of genomic alterations by next-generation sequencing in tumor tissue versus cell-free DNA in stage I–IV non-small cell lung cancer. J Mol Diagn 22(2):228–235. https://doi.org/10.1016/j.jmoldx.2019.10.013. (PMID: 10.1016/j.jmoldx.2019.10.01331837429) ; Kim HS, Mitsudomi T, Soo RA, Cho BC (2013) Personalized therapy on the horizon for squamous cell carcinoma of the lung. Lung Cancer 80(3):249–255. https://doi.org/10.1016/j.lungcan.2013.02.015. (PMID: 10.1016/j.lungcan.2013.02.01523489560) ; Li RY, Liang ZY (2020) Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response. Chin Med J (engl) 133(20):2476–2485. https://doi.org/10.1097/CM9.0000000000001097. (PMID: 10.1097/CM9.000000000000109732960843) ; Li Y, Xu Y, Wu X, He C, Liu Q, Wang F (2019) Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients. J Thorac Dis 11(7):3004–3014. https://doi.org/10.21037/jtd.2019.07.42. (PMID: 10.21037/jtd.2019.07.42314631306688018) ; Meng H, Guo X, Sun D, Liang Y, Lang J, Han Y, Lu Q, Zhang Y, An Y, Tian G, Yuan D, Xu S, Geng J (2019) Genomic profiling of driver gene mutations in chinese patients with non-small cell lung cancer. Front Genet 10:1008. https://doi.org/10.3389/fgene.2019.01008. (PMID: 10.3389/fgene.2019.01008317498316842958) ; Pecuchet N, Zonta E, Didelot A, Combe P, Thibault C, Gibault L, Fabre E (2016) Base-position error rate analysis of next-generation sequencing applied to circulating tumor DNA in non-small cell lung cancer: a prospective study. PLoS Med 13(12):e1002199. https://doi.org/10.1371/journal.pmed.1002199. (PMID: 10.1371/journal.pmed.1002199280273135189949) ; Remon J, Lacroix L, Jovelet C, Caramella C, Howarth K, Plagnol V, Besse B (2019) Real-world utility of an amplicon-based next-generation sequencing liquid biopsy for broad molecular profiling in patients with advanced non-small-cell lung cancer. JCO Precis Oncol. https://doi.org/10.1200/PO.18.00211. (PMID: 10.1200/PO.18.00211329140377446523) ; Rolfo C, Mack PC, Scagliotti GV, Baas P, Barlesi F, Bivona TG, Gandara DR (2018) Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC. J Thorac Oncol 13(9):1248–1268. https://doi.org/10.1016/j.jtho.2018.05.030. (PMID: 10.1016/j.jtho.2018.05.03029885479) ; Rolfo C, Mack P, Scagliotti GV, Aggarwal C, Arcila ME, Barlesi F, Gandara D (2021) Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer. J Thorac Oncol 16(10):1647–1662. https://doi.org/10.1016/j.jtho.2021.06.017. (PMID: 10.1016/j.jtho.2021.06.01734246791) ; Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Spanish Lung Cancer, G (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958–967. https://doi.org/10.1056/NEJMoa0904554. (PMID: 10.1056/NEJMoa090455419692684) ; Schrock AB, Welsh A, Chung JH, Pavlick D, Bernicker EH, Creelan BC, Forcier B, Ross JS, Stephens PJ, Ali SM, Dagogo-Jack I, Shaw AT, Li T, Ou S-HI, Miller VA (2019) Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer. J Thorac Oncol 14(2):255–264. https://doi.org/10.1016/j.jtho.2018.10.008. (PMID: 10.1016/j.jtho.2018.10.00830368012) ; Scilla KA, Rolfo C (2019) The role of circulating tumor DNA in lung cancer: mutational analysis, diagnosis, and surveillance now and into the future. Curr Treat Options Oncol 20(7):61. https://doi.org/10.1007/s11864-019-0653-2. (PMID: 10.1007/s11864-019-0653-231203467) ; Shen M, Qi R, Ren J, Lv D, Yang H (2021) Characterization with KRAS mutant is a critical determinant in immunotherapy and other multiple therapies for non-small cell lung cancer. Front Oncol 11:780655. https://doi.org/10.3389/fonc.2021.780655. (PMID: 10.3389/fonc.2021.78065535070984) ; Wang ZF, Ren SX, Li W, Gao GH (2018) Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis. BMC Cancer 18(1):148. https://doi.org/10.1186/s12885-018-4075-5. (PMID: 10.1186/s12885-018-4075-5294094665801841) ; Zhang YC, Zhou Q, Wu YL (2017) The emerging roles of NGS-based liquid biopsy in non-small cell lung cancer. J Hematol Oncol 10(1):167. https://doi.org/10.1186/s13045-017-0536-6. (PMID: 10.1186/s13045-017-0536-6290611135654124) Grant Information: No. 2020TD07 "Four Batches" of the Science And Technology Innovation Plan of Shanxi Provincial Health Commission Contributed Indexing: Keywords: Circulating tumor DNA; Droplet digital PCR; Next-generation sequencing; Non-small cell lung cancer Substance Nomenclature: 0 (Biomarkers, Tumor) ; 0 (Circulating Tumor DNA) ; EC 2.7.10.1 (ErbB Receptors) ; EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) Entry Date(s): Date Created: 20230515 Date Completed: 20230731 Latest Revision: 20230731 Update Code: 20231215

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.